Company News

  • Reset
GOLDEN, Colo. — August 23, 2021 - PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner, Zydus Cadila has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D the world’s first Plasmid DNA Vaccine for COVID-19. The vaccine, ZyCoV-D,
Read more
GOLDEN, Colo. — July 7, 2021 - PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner Zydus Cadila has applied for Emergency Use Authorization (EUA) to the office of the Drug Controller General of India (DCGI) for its plasmid DNA Vaccine against COVID-19. The vaccine, ZyCoV-D,
Read more
GOLDEN, Colo. — June 30, 2021 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that patient enrollment has started for the phase 1 trial in Australia using its Needle-free Injection Systems to deliver a vaccine against SARS-CoV-2. COVIGEN, a DNA-based vaccine was developed by French-Thai pharmaceutical company
Read more
GOLDEN, Colo. — June 3, 2021- A systematic review and meta-analysis published in the April 30, 2021 issue of The Lancet strengthens evidence from previous publications that fractional dose delivery is a viable alternative to full dose inactivated polio vaccine (IPV). Previous studies have shown that two doses of intradermally-delivered
Tags: Polio, Tropis
Read more
GOLDEN, Colo. — March 9, 2021 — PharmaJet ® , the maker of innovative, needle-free injection technology, today announced that a global NGO (Non-governmental organization) has expanded the use of its Tropis® Needle-free Injection System in polio eradication campaigns. The latest country addition, Somalia, adds to the already successful vaccination
Tags: Polio, Tropis
Read more
GOLDEN, Colo. — October 6, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Stratis® Needle-free Injection System will be used to deliver a vaccine against SARS-CoV-2 in a clinical trial in Australia. The DNA-based vaccine COVIGEN was developed by French-Thai pharmaceutical company BioNet and
Read more
GOLDEN, Colo. — May 19, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Needle-free Injection System technology will be used to deliver a messenger RNA (mRNA) vaccine against SARS-CoV-2. The vaccine is being developed by Abnova Corporation, the world’s largest antibody manufacturer, based in
Read more
GOLDEN, Colo. — March 17, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, announced that it received a $9.6 million dollar contract award from the Joint Science and Technology Office of the U.S. Defense Threat Reduction Agency (DTRA). DTRA, through the Medical CBRN Defense Consortium (MCDC), is funding
Read more
GOLDEN, Colo. — February 5, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced the publication of independent survey results from the first large-scale campaign using its needle-free technology. The paper, entitled Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine (fIPV) in Karachi, Pakistan:
Tags: Polio, Tropis
Read more
GOLDEN, Colo. — January 8, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, announced that the results of the Invectys Phase I clinical trial of its therapeutic cancer vaccine, INVAC-1, using the PharmaJet needle-free injection system, were recently published. The study entitled A First-in-Human Phase I Study of
Read more
GOLDEN, Colo. — Feb. 20, 2018 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced a global license agreement with Genexine, a leading biotherapeutics company headquartered in South Korea, for the development and commercialization of DNA vaccines for human applications using the PharmaJet needle-free injection systems.
Read more
GOLDEN, Colo. — Feb. 6, 2018 — PharmaJet, the maker of innovative, needle-free injection technology, today announced that Vaccibody AS is expanding their human clinical trial (phase IIa) for the study of a vaccine to treat HPV disease using the PharmaJet Stratis® needle-free injection system.
Read more
Menu